Navigation Links
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Date:2/6/2008

ith regard to efficacy, lipid effects, safety and tolerability. Additional study results include:

Achievement of Undetectable Viral Load in Patients with High Baseline Viral Load
* In the study, 74 percent of the 223 patients with high baseline viral

load (greater than or equal to 100,000 copies/mL) in the once-daily

REYATAZ(R) (atazanavir sulfate)/r arm achieved undetectable viral load

at 48 weeks, vs. 72 percent of the 225 patients with high baseline

viral load in the twice-daily lopinavir/r arm.

Immunologic Response

* The mean increase in CD4+ count from baseline at 48 weeks was

203 cells/mm3 in patients in the REYATAZ/r arm and 219 cells/mm3 in

patients in the lopinavir/r arm.

Lipid Effects

* Seven percent of patients in the REYATAZ/r arm vs. eighteen percent of

patients in the lopinavir/r arm had total cholesterol greater than or

equal to 240 mg/dL.

* Less than one percent of patients in the REYATAZ/r arm vs. four percent

of patients in the lopinavir/r arm had triglyceride levels greater than

or equal to 751 mg/dL.

Safety and Tolerability

* 26% of patients in the REYATAZ/r arm and 30% of patients in the

lopinavir/r arm experienced any grade 2-4 treatment-related adverse

event.

* The incidence of treatment discontinuation due to adverse events was

two percent in the REYATAZ/r arm and three percent in the lopinavir/r

arm.

* Renal adverse events of any grade were experienced in two percent of

patients in both treatment arms.

* 34% of patients in the once-daily REYATAZ/r arm and less than 1% of

patients in the twice-daily lopinavir/r arm experienced elevations in

total bilirubin greater than 2.5 times the upper limit of normal.

* The rates of grade 3-4 liver enzyme elevations (greater than 5 times

the upper limi
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
2. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
3. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Inverseon Announces Positive Phase IIa Asthma Study
6. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
7. Study Says Allergy Shots Help Children, Reduce Health Care Costs
8. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
9. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
10. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
11. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  Vaccinogen, Inc. (OTC.QB: VGEN), a ... of Directors has unanimously elected Co-founder, President, Chief Executive ... to the role of Chairman of the Board. Mr. ... who resigned from the Board and his role as ... role to pursue his candidacy for the President of ...
(Date:5/5/2015)... Bio-Techne Corporation (NASDAQ: TECH ) announced ... a dividend of $0.32 per share for the quarter ... payable May 29, 2015 to all common shareholders of ... be considered by the Board of Directors on a ... ) is a global life sciences company providing innovative ...
(Date:5/5/2015)... , May 05, 2015 Research and Markets ... of the "Will Theranos Turn the Lab Industry ... Theranos has received much praise along with a healthy ... "gone public" with their potentially disruptive laboratory solution. Behind ... Has Theranos scaled microfluidic technology across a ...
Breaking Medicine Technology:Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board 2Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board 3Will Theranos Turn the Lab Industry Upside Down? 2
... Mass. , June 1 SynapDx Corp., a new company ... autism, announced the completion of a $9 million Series A ... Partners. , , , ... profound effect on children and their families," said Stanley N. Lapidus ...
... FRANCISCO , June 1 Prostate cancer ... FIRMAGON® (degarelix for injection) after one year of treatment ... of a Phase III extension study(1) presented here at ... used in monitoring prostate cancer patients, treatment response, and ...
Cached Medicine Technology:Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 2Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 3Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 4Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 5
(Date:5/5/2015)... On May, 5, 2015, My Positive Perspective host ... about alternatives for youngsters to do this summer. As the ... idea for starting a summer camp and how is it ... called Once Upon a Party and I come to children’s ... even scripture. We play games, sing, and dance and have ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 For the growing ... HiTemp140 series of data loggers. This data logger ... the electronic components for optimum performance throughout exposure to high ... data loggers are capable of storing up to 32,700 ... battery life of one year or longer. All data loggers ...
(Date:5/5/2015)... May 05, 2015 In the upbeat Moms ... is for moms to support each other. Parenting is ... other’s side makes it so much easier. Mothers talk ... better, feel less alone and help them realize there’s no ... Moms who are clearly dear friends share that it's ...
(Date:5/5/2015)... Buckeye Health Plan (BHP) is pleased to ... president of Buckeye Health Plan. Hill, known for growing ... Hill has more than 28 years of healthcare leadership ... managed care to large health care provider systems. Most ... of Michigan, a health plan serving the Medicaid, Medicare ...
(Date:5/5/2015)... KNOXVILLE, Tenn. (PRWEB) May 05, 2015 ... company that provides innovative interoperability solutions for hospitals ... ROI cost savings calculator. Hospital CIOs and CTOs ... at healthslide.com. The calculator shows both initial and ... offering, Boomerang. , “Our nation’s hospitals pay ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 3Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 4Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 5Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 6Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 3Health News:HealthSlide Launches ROI Cost Calculator 2
... 26 Pregis Corporation, a leading international manufacturer, marketer, ... solutions, today announced its 2008 fourth quarter and full ... Company generated net sales of $219.6 million, a decrease ... the fourth quarter of 2007. Excluding incremental revenue ...
... March 26 Abusing real-time communication tools like instant ... of sales reps to engage with physicians."A lot of ... more efficient," stated a sales executive in a roundtable ... "In reality, they,re so distracted by doing four things ...
... suppresses enzyme vital to tumor growth , , THURSDAY, March 26 ... also help slow the spread of a deadly type of ... published in the current issue of the International Journal ... telomerase. Telomerase activity appears to be essential for certain tumor ...
... PLEASANTON, Calif., FRAMINGHAM, Mass. and SYDNEY, Australia, ... ), a leader in device-based mechanical circulatory support therapies ... International, Inc. (Nasdaq: HTWR ; ASX: HIN), ... today that they each received a Request for Additional ...
... Patient Health and Safety and Pharmaceutical Innovation ... Generic Pharmaceutical Association (GPhA) released the following ... Kathleen Jaeger regarding the bipartisan Senate introduction ... Life-Saving Medicine Act.""Momentum is skyrocketing for biogenerics ...
... Safeguard and Comerica Debt Facilities; Support Robust GrowthALISO VIEJO, ... CLRT ), a premier anatomic pathology and ... pharmaceutical industry, announced today that it has entered into ... Oak Investment Partners , a multi-stage venture capital ...
Cached Medicine News:Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 2Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 3Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 4Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 5Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 6Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 7Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 8Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 9Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 10Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 11Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 12Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 13Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 14Health News:Pregis Announces Fourth Quarter and Full Year 2008 Financial Results 15Health News:Sales Force Effectiveness: Less Texting, More Engagement 2Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 2Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 3Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 4Health News:Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission 5Health News:GPhA Statement on the Introduction of the Bipartisan Senate Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act' 2Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 2Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 3Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 4Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 5Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 6Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 7Health News:Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners 8
Topics include: ECG reading, ACLS (all the latest protocols and pearls), CHF, acute MI, cardiac testing, palpitations, pericarditis, arrhythmias, murmurs, athletes, valvular disease, endocarditis, sy...
Cardiology Intensive Board Review is geared specifically to candidates taking the Cardiovascular Boards and the Cardiovascular section of the Internal Medicine Boards....
... provides leading edge information ... involving all aspects of ... on diagnosis and management ... venous disease. CVMstat® reviews ...
A Practical Approach to TEE puts detailed "how-to" information on transesophageal echocardiography (TEE) at the clinician's fingertips in the operating room, intensive care unit, office, or any other...
Medicine Products: